Results 71 to 80 of about 3,844,628 (256)

Direct-acting antivirals for RSV treatment, a review

Antiviral Research
Respiratory syncytial virus (RSV) causes respiratory disease and complications in infants, the elderly and the immunocompromised. While three vaccines and two prophylactic monoclonal antibodies are now available, only one antiviral, ribavirin, is currently approved for treatment.
Brecht Bonneux, Edgar Jacoby, Martina Ceconi, Kim Stobbelaar, Peter Delputte, Florence Herschke   +5 more
openaire   +3 more sources

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

Molecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler, Bilal A. Lone, Ecem Unal, A. Rouf Banday   +3 more
wiley   +1 more source

Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C

, 2021
Hepatitis C virus (HCV) infection is a major public health concern worldwide, raising important medical and economic issues. HCV-related end-stage liver disease is one of the most common indications for hepatic transplantation.
Myriam Ayari, Myriam Jrad, Walid Cherifi, Feryel Letaief Ksontini, Yosra Zaimi, Shema Ayadi, Emna Bel Hadj Mabrouk   +6 more
core   +1 more source

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

FEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

New treatment of hepatitis C (Direct Acting Antiviral)

Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd, 2019
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for the patients with HCV-related liver disease has advanced considerably thanks to an ...
Mohsen Akhondi-Meybodi
doaj  

Hepatitis C direct‐acting antiviral outcomes in patients 75 years and older

JGH Open, 2021
Background and Aim Elderly patients with hepatitis C virus (HCV) infection have worse interferon‐based treatment outcomes than young patients. Direct‐acting antiviral (DAA) regimens have enabled the treatment of previously difficult‐to‐cure populations ...
Parmvir Parmar, Stephen D Shafran, Sergio M Borgia, Karen Doucette, Curtis L Cooper   +4 more
doaj   +1 more source

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis [PDF]

Scientifica, 2012
The development and evaluation of antiviral agents through carefully designed clinical trials over the last 25 years have heralded a new dawn in the treatment of patients chronically infected with the hepatitis B and C viruses, but not so for the D virus (HBV, HCV, and HDV).
openaire   +3 more sources

Yeast Gcn2 retains activity following humanization of its auto‐phosphorylation region

FEBS Open Bio, EarlyView.
Using Saccharomyces cerevisiae as a model to study Gcn2 activation and regulation is limited by the lack of antibodies detecting phosphorylated Gcn2. To overcome this, we engineered Gcn2‐HsC, a yeast Gcn2 variant recognizable by commercial anti‐human phospho‐GCN2 antibodies.
Reuben A. Anderson, Anja H. Schiemann, Evelyn Sattlegger   +2 more
wiley   +1 more source

Cost-effectiveness of treating hepatitis C in Seychelles

The Pan African Medical Journal, 2019
INTRODUCTION: Approximately eighty million people around the world are living with hepatitis C, and 700,000 people die every year, due to hepatitis C related complications.
Naomi Joan Faray Adeline, Claudia Geue, Mohsen Rezaei Hermami   +2 more
doaj   +1 more source

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.

PLoS ONE, 2020
The advent of direct-acting antiviral (DAA) therapies has dramatically transformed HCV treatment, with most recent trials demonstrating high efficacy rates (>90%) across all genotypes and special populations, including patients with HIV/HCV coinfection ...
Sonia Vibhakar Patel, Dushyantha T Jayaweera, Keri N Althoff, Joseph J Eron, Janna Radtchenko, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E Sax, Jason Gillman, Karam Mounzer, Richard A Elion, Gregory D Huhn   +12 more
doaj   +1 more source